Guo Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Guo Wang has a total of 81 co-authors. Here are the top co-authors by number of shared publications:
Ying Zeng
Department of Pharmacy, The Affiliated Changsha Central Hospital, Hengyang Medical School, University of South China, Changsha, China
11 shared publicationsHai-Bo Zhang
Department of Pharmacy, Hangzhou Women's Hospital (Hangzhou Maternity and Child Health Care Hospital), Hangzhou, China
9 shared publicationsJun-Li Deng
Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, P.R. China
7 shared publications- Yuan-Shan Zhu
Department of Medicine/Endocrinology, Weill Cornell Medical College, New York, New York
7 shared publications Yun-Hua Xu
Department of Pharmacology, School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
5 shared publicationsHong Sun
Department of Pharmacy, Fujian Provincial Hospital, Shengli Clinical Medical College of Fujian Medical University, Fuzhou, People’s Republic of China
4 shared publications
Latest Publications
- Open Access
- 26 June 2026
- Published by Springer Nature in Discover Oncology
- Vol. 17 (1)
Common genetic variation of the IGF2 gene and epithelial ovarian cancer risk in Chinese population
Epithelial ovarian cancer (EOC) is a gynecological malignancy associated with high mortality, largely due to frequent diagnosis at advanced stages resulting from its asymptomatic early presentation. Although several single nucleotide polymorphisms (SNPs) have been implicated in EOC risk, its genetic determinants remain incompletely characterized. This study aimed to investigate the association between IGF2 polymorphisms (rs1004446, rs10840447, rs11602347, and rs4244808) and both susceptibility and clinicopathological characteristics of EOC in a Chinese population. Genomic DNA was extracted from peripheral whole blood samples. The four candidate SNPs in IGF2 were genotyped in 213 EOC patients (211 serous) and 203 healthy controls using the MassARRAY platform. The genotype frequencies of rs11602347 C > G (P < 0.0001) and rs4244808 T > G (P = 0.010) differed significantly between cases and controls. Genetic model analyses revealed that the rs11602347 C > G variant was associated with a reduced risk of EOC under dominant and additive models (CG + GG vs. CC: adjusted OR = 0.09, Benjamini-Hochberg adjusted P = 0.002; GG vs. CC: adjusted OR = 0.11, Benjamini-Hochberg adjusted P = 0.008), while the rs4244808 T > G variant was correlated with an increased risk under the recessive model (GG vs. TG + TT: adjusted OR = 2.51, Benjamini-Hochberg adjusted P = 0.016). Stratified analysis indicated that the protective effect of rs10840447 GG genotype was more pronounced in younger individuals (age ≤ 47: adjusted OR = 0.47, P = 0.028), whereas the TG + TT genotypes of rs4244808 were associated with significantly elevated EOC risk in older individuals (age > 47 :adjusted OR = 3.52, P = 0.015). Furthermore, among EOC cases, the GG genotype of rs11602347 was associated with an increased odds of advanced FIGO stage (III+IV vs. I+II: adjusted OR = 2.67, P = 0.034), while the GG genotype of rs4244808 was linked to a reduced odds of advanced FIGO stage (III + IV vs. I+ II: adjusted OR = 0.30, P = 0.032). Haplotype analysis showed that the GGGG* haplotype (rs1004446/rs10840447/rs11602347/rs4244808) was associated with an increased risk of EOC (OR = 2.16, P = 0.036). These findings provide preliminary evidence that IGF2 gene polymorphisms may be associated with the risk and clinicopathological characteristics of serous EOC in Chinese women.
- 26 June 2026
- Published by Springer Nature in Discover Oncology
- Vol. 17 (1)
Open AccessCommon genetic variation of the IGF2 gene and epithelial ovarian cancer risk in Chinese population
Epithelial ovarian cancer (EOC) is a gynecological malignancy associated with high mortality, largely due to frequent diagnosis at advanced stages resulting from its asymptomatic early presentation. Although several single nucleotide polymorphisms (SNPs) have been implicated in EOC risk, its genetic determinants remain incompletely characterized. This study aimed to investigate the association between IGF2 polymorphisms (rs1004446, rs10840447, rs11602347, and rs4244808) and both susceptibility and clinicopathological characteristics of EOC in a Chinese population. Genomic DNA was extracted from peripheral whole blood samples. The four candidate SNPs in IGF2 were genotyped in 213 EOC patients (211 serous) and 203 healthy controls using the MassARRAY platform. The genotype frequencies of rs11602347 C > G (P < 0.0001) and rs4244808 T > G (P = 0.010) differed significantly between cases and controls. Genetic model analyses revealed that the rs11602347 C > G variant was associated with a reduced risk of EOC under dominant and additive models (CG + GG vs. CC: adjusted OR = 0.09, Benjamini-Hochberg adjusted P = 0.002; GG vs. CC: adjusted OR = 0.11, Benjamini-Hochberg adjusted P = 0.008), while the rs4244808 T > G variant was correlated with an increased risk under the recessive model (GG vs. TG + TT: adjusted OR = 2.51, Benjamini-Hochberg adjusted P = 0.016). Stratified analysis indicated that the protective effect of rs10840447 GG genotype was more pronounced in younger individuals (age ≤ 47: adjusted OR = 0.47, P = 0.028), whereas the TG + TT genotypes of rs4244808 were associated with significantly elevated EOC risk in older individuals (age > 47 :adjusted OR = 3.52, P = 0.015). Furthermore, among EOC cases, the GG genotype of rs11602347 was associated with an increased odds of advanced FIGO stage (III+IV vs. I+II: adjusted OR = 2.67, P = 0.034), while the GG genotype of rs4244808 was linked to a reduced odds of advanced FIGO stage (III + IV vs. I+ II: adjusted OR = 0.30, P = 0.032). Haplotype analysis showed that the GGGG* haplotype (rs1004446/rs10840447/rs11602347/rs4244808) was associated with an increased risk of EOC (OR = 2.16, P = 0.036). These findings provide preliminary evidence that IGF2 gene polymorphisms may be associated with the risk and clinicopathological characteristics of serous EOC in Chinese women.
- Open Access
- 8 January 2026
- Published by Springer Nature in Discover Oncology
- Vol. 17 (1) , 50
Identification of GPD1L as a potential prognosis biomarker and associated with colorectal cancer progression
Background Colorectal cancer (CRC) ranks high in both global incidence and mortality rates. The discovery of potential biomarkers and therapeutic targets can effectively improve early diagnosis, treatment efficacy, and prognosis for CRC patients. Methods Genes that were abnormally expressed in CRC tumors and associated with patients’ prognosis were first screened in The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases; Clinical CRC samples were used to validate the results. The correlation between clinical characteristics and candidate genes, as well as their role in CRC cell proliferation, migration, invasion capability, and the cell cycle were analyzed. Results The study indicated that glycerol-3-phosphate dehydrogenase 1-like (GPD1L) was significantly down-regulated in CRC tumor tissues and served as an independent prognostic factor for OS and RFS of CRC patients. It was also associated with TNM staging, lymph node metastasis, tumor size, and tumor location. Inhibiting GPD1L expression significantly up-regulated the proliferation, migration, and invasion capabilities of CRC cells. Conclusions GPD1L may serve as a prognostic biomarker for patients with CRC and participate in the regulation of CRC cell proliferation, migration, and invasion capability.
- 8 January 2026
- Published by Springer Nature in Discover Oncology
- Vol. 17 (1) , 50
Open AccessIdentification of GPD1L as a potential prognosis biomarker and associated with colorectal cancer progression
Background Colorectal cancer (CRC) ranks high in both global incidence and mortality rates. The discovery of potential biomarkers and therapeutic targets can effectively improve early diagnosis, treatment efficacy, and prognosis for CRC patients. Methods Genes that were abnormally expressed in CRC tumors and associated with patients’ prognosis were first screened in The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases; Clinical CRC samples were used to validate the results. The correlation between clinical characteristics and candidate genes, as well as their role in CRC cell proliferation, migration, invasion capability, and the cell cycle were analyzed. Results The study indicated that glycerol-3-phosphate dehydrogenase 1-like (GPD1L) was significantly down-regulated in CRC tumor tissues and served as an independent prognostic factor for OS and RFS of CRC patients. It was also associated with TNM staging, lymph node metastasis, tumor size, and tumor location. Inhibiting GPD1L expression significantly up-regulated the proliferation, migration, and invasion capabilities of CRC cells. Conclusions GPD1L may serve as a prognostic biomarker for patients with CRC and participate in the regulation of CRC cell proliferation, migration, and invasion capability.
- 28 October 2025
- Published by Springer Nature in World Journal of Microbiology and Biotechnology
- Vol. 41 (11) , 1-15
Mendelian randomization combined with real-world study reveals that Streptococcus anginosus exacerbates dietary triglyceride metabolism disorders in obese mice
Mendelian Randomization (MR) analysis can link the host gut microbiome to cardiovascular diseases. Streptococcus anginosus (S. anginosus) has been found to be positively correlated with early atherosclerosis, but its role in lipid metabolism remains to be explored. To investigate the impact of S. anginosus on lipid metabolism, we employed M methods using large-scale population genome-wide association study (GWAS) sequencing data, combined with a C57BL/6J mouse obesity model to assess the role of S. anginosus in lipid metabolism. Throughout the entire experiment, we monitored the dynamic changes in serum blood lipids in mice and the abundance of S. anginosus in feces. We evaluated the accumulation of lipid droplets in the liver and adipose tissue, as well as examined the gene-level expression changes of lipid metabolism enzymes and transcription factors. The findings from MR analysis indicate that ten specific gut microbial taxa including Streptococcaceae exhibit a causal relationship with disorders of lipoprotein metabolism. Notably, Streptococcaceae has been identified as a risk factor for it. Furthermore, S. anginosus has been shown to elevate serum triglycerides (TG) levels, diminish the accumulation of lipid droplets in both hepatic and adipose tissues, and downregulate the gene expression of enzymes involved in TG synthesis and metabolism. These findings suggest that S. anginosus is a risk factor for lipoprotein disorders and reduces dietary lipid metabolism in a mouse obesity model, leading to TG metabolism dysfunction. This study combines bioinformatics analysis and animal experiments to provide new insights into S. anginosus as a risk factor for lipid metabolism disorders.
- 28 October 2025
- Published by Springer Nature in World Journal of Microbiology and Biotechnology
- Vol. 41 (11) , 1-15
Mendelian randomization combined with real-world study reveals that Streptococcus anginosus exacerbates dietary triglyceride metabolism disorders in obese mice
Mendelian Randomization (MR) analysis can link the host gut microbiome to cardiovascular diseases. Streptococcus anginosus (S. anginosus) has been found to be positively correlated with early atherosclerosis, but its role in lipid metabolism remains to be explored. To investigate the impact of S. anginosus on lipid metabolism, we employed M methods using large-scale population genome-wide association study (GWAS) sequencing data, combined with a C57BL/6J mouse obesity model to assess the role of S. anginosus in lipid metabolism. Throughout the entire experiment, we monitored the dynamic changes in serum blood lipids in mice and the abundance of S. anginosus in feces. We evaluated the accumulation of lipid droplets in the liver and adipose tissue, as well as examined the gene-level expression changes of lipid metabolism enzymes and transcription factors. The findings from MR analysis indicate that ten specific gut microbial taxa including Streptococcaceae exhibit a causal relationship with disorders of lipoprotein metabolism. Notably, Streptococcaceae has been identified as a risk factor for it. Furthermore, S. anginosus has been shown to elevate serum triglycerides (TG) levels, diminish the accumulation of lipid droplets in both hepatic and adipose tissues, and downregulate the gene expression of enzymes involved in TG synthesis and metabolism. These findings suggest that S. anginosus is a risk factor for lipoprotein disorders and reduces dietary lipid metabolism in a mouse obesity model, leading to TG metabolism dysfunction. This study combines bioinformatics analysis and animal experiments to provide new insights into S. anginosus as a risk factor for lipid metabolism disorders.
- Open Access
- 29 August 2025
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 23 (1) , 1-2
Correction: Knockdown of PVT1 inhibits cell proliferation in luminal and basal-like breast cancer subtypes by activating LATS2/Hippo signaling pathway
- 29 August 2025
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 23 (1) , 1-2
Open AccessCorrection: Knockdown of PVT1 inhibits cell proliferation in luminal and basal-like breast cancer subtypes by activating LATS2/Hippo signaling pathway
- Open Access
- 19 July 2025
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 23 (1) , 289
Knockdown of PVT1 inhibits cell proliferation in luminal and basal-like breast cancer subtypes by activating LATS2/Hippo signaling pathway
Breast cancer (BC) is a malignant tumor seriously threatening women's health, while current approaches to BC treatment are challenged by the existence of drug resistance. Combination strategies of targeted therapy have been successfully applied in clinical BC treatment. However, whether there exist critical long non-coding RNAs (lncRNAs) responsible for BC pathogenesis and representing promising candidates for combined targeted therapy remains an issue. Public databases and bioinformatic methods were used to identify lncRNAs abnormally expressed among different subtypes of BC. The expression level of PVT1 was verified in collected clinical samples and representative cell lines. The role of PVT1 in BC cell proliferation was examined using MTS, plate clone formation, EdU and flow cytometry assay after small interfering RNA (siRNA) treatment. RNA sequencing was performed to investigate the potential molecular events regulated by PVT1. Western blot and immunofluorescence experiments were used to verify the activation of LATS2/Hippo signaling pathway after PVT1 knockdown. In addition, its activation was confirmed to mediate PVT1 function through rescue assay. The regulatory effect of PVT1 on LATS2 was investigated using mRNA stability experiments. The expression level of PVT1 in BC tissues of luminal and basal-like subtypes was significantly higher than that in paracancerous tissues. PVT1 knockdown substantially inhibited the proliferation of BC cells in both subtypes. RNA sequencing revealed that Hippo signaling pathway might be the downstream target of PVT1. After PVT1 knockdown, both mRNA and protein levels of LATS2 were elevated which further decreased the distribution of YAP in cell nucleus, indicating the activation of Hippo signaling pathway. The proliferation inhibitory effect of PVT1 could be attenuated by simultaneous knockdown of LATS2. Furthermore, knockdown of PVT1 was demonstrated to significantly slow down the degradation rate of LATS2 mRNA. PVT1 level was significantly elevated in luminal and basal-like BC subtypes. Knockdown of PVT1 could inhibit cell proliferation of these two BC subtypes partly through activating LATS2/Hippo signaling pathway.
- 19 July 2025
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 23 (1) , 289
Open AccessKnockdown of PVT1 inhibits cell proliferation in luminal and basal-like breast cancer subtypes by activating LATS2/Hippo signaling pathway
Breast cancer (BC) is a malignant tumor seriously threatening women's health, while current approaches to BC treatment are challenged by the existence of drug resistance. Combination strategies of targeted therapy have been successfully applied in clinical BC treatment. However, whether there exist critical long non-coding RNAs (lncRNAs) responsible for BC pathogenesis and representing promising candidates for combined targeted therapy remains an issue. Public databases and bioinformatic methods were used to identify lncRNAs abnormally expressed among different subtypes of BC. The expression level of PVT1 was verified in collected clinical samples and representative cell lines. The role of PVT1 in BC cell proliferation was examined using MTS, plate clone formation, EdU and flow cytometry assay after small interfering RNA (siRNA) treatment. RNA sequencing was performed to investigate the potential molecular events regulated by PVT1. Western blot and immunofluorescence experiments were used to verify the activation of LATS2/Hippo signaling pathway after PVT1 knockdown. In addition, its activation was confirmed to mediate PVT1 function through rescue assay. The regulatory effect of PVT1 on LATS2 was investigated using mRNA stability experiments. The expression level of PVT1 in BC tissues of luminal and basal-like subtypes was significantly higher than that in paracancerous tissues. PVT1 knockdown substantially inhibited the proliferation of BC cells in both subtypes. RNA sequencing revealed that Hippo signaling pathway might be the downstream target of PVT1. After PVT1 knockdown, both mRNA and protein levels of LATS2 were elevated which further decreased the distribution of YAP in cell nucleus, indicating the activation of Hippo signaling pathway. The proliferation inhibitory effect of PVT1 could be attenuated by simultaneous knockdown of LATS2. Furthermore, knockdown of PVT1 was demonstrated to significantly slow down the degradation rate of LATS2 mRNA. PVT1 level was significantly elevated in luminal and basal-like BC subtypes. Knockdown of PVT1 could inhibit cell proliferation of these two BC subtypes partly through activating LATS2/Hippo signaling pathway.
- 5 March 2025
- Published by Elsevier in European Journal of Pharmacology
- Vol. 997, 177475
Pharmacological modulation of cellular senescence: Implications for breast cancer progression and therapeutic strategies
- 5 March 2025
- Published by Elsevier in European Journal of Pharmacology
- Vol. 997, 177475
Pharmacological modulation of cellular senescence: Implications for breast cancer progression and therapeutic strategies
- Open Access
- 1 April 2022
- Published by IOP Publishing in Journal of Physics: Conference Series
- Vol. 2264 (1) , 012023
Research and Implementation of Containerization for Virtual Instrumentation Measurement
The instrumentation measurement system has fruitful achievements in various fields with cloud computing technology. However, the instrumentation cloud needs more PaaS (Platform-as-a-Service) capabilities to improve development and IT operations efficiency by expanding distributed measurement systems. In recent years, container and cloud-native technology growth have brought developing chances for instrumentation cloud. We propose a novel container and instrumentation communication architecture to apply container technology to virtual instrumentation. Firstly, we analyze the critical technologies of Container-Instrumentation communication architecture and give the solution of its implementation. Secondly, we develop and deploy the web backend and frontend to visualize measurement data with Kubernetes. Finally, completing the IV sweep measurement on the web demonstrates the feasibility of building the measurement system in a cloud-native way. So, the container-instrumentation architecture provides practical significance for constructing measurement systems and improving the instrumentation cloud capabilities with cloud-native architecture in the future.
- 1 April 2022
- Published by IOP Publishing in Journal of Physics: Conference Series
- Vol. 2264 (1) , 012023
Open AccessResearch and Implementation of Containerization for Virtual Instrumentation Measurement
The instrumentation measurement system has fruitful achievements in various fields with cloud computing technology. However, the instrumentation cloud needs more PaaS (Platform-as-a-Service) capabilities to improve development and IT operations efficiency by expanding distributed measurement systems. In recent years, container and cloud-native technology growth have brought developing chances for instrumentation cloud. We propose a novel container and instrumentation communication architecture to apply container technology to virtual instrumentation. Firstly, we analyze the critical technologies of Container-Instrumentation communication architecture and give the solution of its implementation. Secondly, we develop and deploy the web backend and frontend to visualize measurement data with Kubernetes. Finally, completing the IV sweep measurement on the web demonstrates the feasibility of building the measurement system in a cloud-native way. So, the container-instrumentation architecture provides practical significance for constructing measurement systems and improving the instrumentation cloud capabilities with cloud-native architecture in the future.
- 22 January 2022
- Published by Springer Nature in Apoptosis
- Vol. 27 (1-2) , 1-13
Pyroptosis, a target for cancer treatment?
Pyroptosis is a newly discovered form of programmed cell death mediated by the gasdermin protein, that is accompanied by inflammation and immune response. A growing body of evidence suggests that pyroptosis is closely related to cancer, and it is becoming a new cancer research topic. Studies have suggested that different cancer cells activate pyroptosis in different ways and that the effects of pyroptosis vary in different cancer backgrounds. In this article, we briefly introduce the definition, characteristics, and activation pathways of pyroptosis. Then we review the complex effects of pyroptosis on cancer development, which generally include inhibition of cancer cell viability, impacts on the invasion and migration of cancer cells, improvement of antitumor immunity, and enhancement of chemotherapy sensitivity. We also discuss drugs and compounds that can induce pyroptosis, as well as the interaction between pyroptosis and apoptosis. Elucidating the mechanisms of the complex effects of pyroptosis is likely to pave the way for therapeutic approaches for cancer in the future.
- 22 January 2022
- Published by Springer Nature in Apoptosis
- Vol. 27 (1-2) , 1-13
Pyroptosis, a target for cancer treatment?
Pyroptosis is a newly discovered form of programmed cell death mediated by the gasdermin protein, that is accompanied by inflammation and immune response. A growing body of evidence suggests that pyroptosis is closely related to cancer, and it is becoming a new cancer research topic. Studies have suggested that different cancer cells activate pyroptosis in different ways and that the effects of pyroptosis vary in different cancer backgrounds. In this article, we briefly introduce the definition, characteristics, and activation pathways of pyroptosis. Then we review the complex effects of pyroptosis on cancer development, which generally include inhibition of cancer cell viability, impacts on the invasion and migration of cancer cells, improvement of antitumor immunity, and enhancement of chemotherapy sensitivity. We also discuss drugs and compounds that can induce pyroptosis, as well as the interaction between pyroptosis and apoptosis. Elucidating the mechanisms of the complex effects of pyroptosis is likely to pave the way for therapeutic approaches for cancer in the future.
- Open Access
- 18 November 2021
- Published by Wiley in Journal of Cellular Physiology
- Vol. 237 (3) , 1992
CORRIGENDUM: Reduced LINC00551 expression promotes proliferation and invasion of esophageal squamous cancer by increase in HSP27 phosphorylation
- 18 November 2021
- Published by Wiley in Journal of Cellular Physiology
- Vol. 237 (3) , 1992
Open AccessCORRIGENDUM: Reduced LINC00551 expression promotes proliferation and invasion of esophageal squamous cancer by increase in HSP27 phosphorylation
- Open Access
- 28 October 2021
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 23 (1) , 1-9
Long non‑coding RNA H19 mediates N‑acetyltransferase 1 gene methylation in the development of tamoxifen resistance in breast cancer
Long non‑coding RNA (lncRNA) H19 is associated with proliferation, invasion and metastasis in numerous types of cancer. H19 lncRNA has been demonstrated to be an estrogen‑inducible gene, the expression of which is significantly increased in tamoxifen (TAM)‑resistant MCF‑7 breast cancer cells. The aim of the present study was to investigate the role and molecular mechanism of lncRNA H19 in the development of TAM resistance. TAM‑resistant MCF‑7 (MCF‑7R) cells were developed by the treatment of wild‑type MCF‑7 cells with 4‑hydroxytamoxifen. Analysis of H19 expression in the cells indicated that upregulation of H19 contributed to the resistance of the MCF‑7R cell line. Furthermore, when H19 was knocked down in the MCF‑7R cells, the sensitivity to 4‑hydroxytamoxifen was markedly restored. The results further demonstrated that N‑acetyltransferase 1 (NAT1) may serve an important role in TAM‑resistant cells, as NAT1 expression was notably downregulated in the MCF‑7R cells but significantly elevated following the knockdown of H19. In addition, lower expression of NAT1 and higher expression of H19 were indicated to be associated with poor prognosis in patients with breast cancer treated with TAM. The results of bisulfite genomic sequencing PCR analysis indicated that the methylation rate of NAT1 in MCF‑7R cells was significantly higher compared with that in MCF‑7 cells, while the methylation rate of NAT1 in TAM‑resistant cells transfected with small interfering RNA against H19 was significantly lower than that in the corresponding untransfected cells. Therefore, the present study suggests that the H19 gene regulates NAT1 expression in TAM‑resistant cells via the mediation of NAT1 promoter methylation.
- 28 October 2021
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 23 (1) , 1-9
Open AccessLong non‑coding RNA H19 mediates N‑acetyltransferase 1 gene methylation in the development of tamoxifen resistance in breast cancer
Long non‑coding RNA (lncRNA) H19 is associated with proliferation, invasion and metastasis in numerous types of cancer. H19 lncRNA has been demonstrated to be an estrogen‑inducible gene, the expression of which is significantly increased in tamoxifen (TAM)‑resistant MCF‑7 breast cancer cells. The aim of the present study was to investigate the role and molecular mechanism of lncRNA H19 in the development of TAM resistance. TAM‑resistant MCF‑7 (MCF‑7R) cells were developed by the treatment of wild‑type MCF‑7 cells with 4‑hydroxytamoxifen. Analysis of H19 expression in the cells indicated that upregulation of H19 contributed to the resistance of the MCF‑7R cell line. Furthermore, when H19 was knocked down in the MCF‑7R cells, the sensitivity to 4‑hydroxytamoxifen was markedly restored. The results further demonstrated that N‑acetyltransferase 1 (NAT1) may serve an important role in TAM‑resistant cells, as NAT1 expression was notably downregulated in the MCF‑7R cells but significantly elevated following the knockdown of H19. In addition, lower expression of NAT1 and higher expression of H19 were indicated to be associated with poor prognosis in patients with breast cancer treated with TAM. The results of bisulfite genomic sequencing PCR analysis indicated that the methylation rate of NAT1 in MCF‑7R cells was significantly higher compared with that in MCF‑7 cells, while the methylation rate of NAT1 in TAM‑resistant cells transfected with small interfering RNA against H19 was significantly lower than that in the corresponding untransfected cells. Therefore, the present study suggests that the H19 gene regulates NAT1 expression in TAM‑resistant cells via the mediation of NAT1 promoter methylation.